Biotechnology Market News

China enhances scientific and technological innovation - People's Daily Online

China enhances scientific and technological innovation People's Daily Online, China - 2 hours ago China also procured biotechnology in order to catch up in the development of high-tech industries. It stepped up research and development. ...

Genetics lab to operate in Bangor temporarily - Bangor Daily News

Genetics lab to operate in Bangor temporarily Bangor Daily News, ME - 2 hours ago "Because of its proximity to educational institutions, biotechnology companies and the Department of Veterans Affairs in Togus, the facility opens the door ...

Unravelling cerebrovascular disease - Laboratory Talk

Unravelling cerebrovascular disease Laboratory Talk, UK - 1 hour ago Revolutionary biochip array technology developed by Randox Laboratories enables simultaneous testing of up to 23 biomarkers for each patient sample. ...

2008 American Society Of Breast Disease Pathfinder Lectures - Medical News Today (press release)

2008 American Society Of Breast Disease Pathfinder Lectures Medical News Today (press release), UK - 1 hour ago Mary-Claire King is Professor of Medicine and Genetics and an American Cancer Society professor at the University of Washington. ...

Guns, Germs, and Steel (and Genetics) - Conde Nast Portfolio

Guns, Germs, and Steel (and Genetics) Conde Nast Portfolio, NY - 1 hour ago Here's a thought experiment: Imagine two societies, one with very little genetic diversity and the other bursting at the double helix. ...

A pound of cloney baloney - The Daily Planet

A pound of cloney baloney The Daily Planet, CO - 2 hours ago By Thom Carnevale a VIAGEN a Preserving and multiplying SUPERIOR genetics. VIAGEN enables the owners of cattle, horses and pigs to preserve and multiply ...

Researchers seek lab rats alternatives - The Age

Researchers seek lab rats alternatives The Age, Australia - Jan 28, 2008 The lab rat of the future may have no whiskers and no tail - and might not even be a rat at all. With a European ban looming on animal testing for cosmetics ...

a Cousin marriages reason for 44pc thalassaemia casesa - Daily Times

a Cousin marriages reason for 44pc thalassaemia casesa Daily Times, Pakistan - 1 hour ago Prof Dr Muhammad Aslam Khan, the head of the UHS Human Genetics and Biotechnology Department, conducted a study on cultural consanguinity in Punjab and ...

Briefs: Groundbreaking for Holocaust Museum, finally - The Jewish Journal of greater L.A

Briefs: Groundbreaking for Holocaust Museum, finally The Jewish Journal of greater L.A, CA - 17 minutes ago The Foundation has since launched the 0 million Google Lunar X PRIZE and the 0 million Archon X PRIZE for Genomics. Kadima Hebrew Academy in West Hills ...

TFN NEWS BRIEFING: Pharmaceuticals and chemicals highlights to 15 ... - Hemscott

TFN NEWS BRIEFING: Pharmaceuticals and chemicals highlights to 15 ... Hemscott, UK - 5 hours ago NEW YORK (Thomson Financial) - CombiMatrix Corp. and Clarient Inc. Thursday established a partnership to market and sell HemeScan, a genomics-based cancer ...

Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Third Quarter Results on Friday, February 8, 2008

BETHESDA, Md., Jan. 31 /Xinhua-PRNewswire/ -- Chindex International, Inc. a leading independent American provider of Western healthcare products and services in the People's Republic of China, announced that it intends to release its financial results for the third quarter ended December 31, 2007, on Friday, February 8, 2008.

Chindex's management will also host a conference call on Friday, February 8, 2008 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time; 11:00 p.m. China time) to discuss its financial results.

To participate, international callers dial 201-689-8566, domestic callers dial 877-407-0709 approximately 10 minutes before the conference call is scheduled to begin.

The telephone replay will be available two hours after the call at (international) 201-612-7415 and (domestic) 877-660-6853, pass code 273077; and continue to be available through February 22, 2008.

This call is also being webcast by Vcall and can be accessed at Chindex's website http://www.chindex.com/news/financial.cfm or at http://www.investorcalendar.com/ . The event will be archived and available for replay through May 9, 2008.

About Chindex International, Inc.

Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. It provides healthcare services through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in the Beijing and Shanghai metropolitan areas. The Company sells medical products manufactured by various major multinational companies, including Siemens AG, which is the Company's exclusive distribution partner for the sale and servicing of color doppler ultrasound systems. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-five years of experience, more than 1,000 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites, http://www.chindex.com/ and http://www.unitedfamilyhospitals.com/ .

Statements made in this press release relating to plans, strategies, objectives, economic performance and trends and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, the terms, conditions, covenants, requirements and limitations set forth in the documents relating to the above financing, risks and uncertainties relating to the development to completion of the proposed two new and/or expanded hospital facilities on budget if at all and factors set forth under the heading "Risk Factors" in our annual report on Form 10-K for the year ended March 31, 2007, updates and additions to those "Risk Factors" in our interim reports on Form 10-Q and in other documents filed by us with the Securities and Exchange Commission from time to time. Forward- looking statements may be identified by terms such as "may", "will", "should", "could", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "forecasts", "potential", or "continue" or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We have no obligation to update these forward-looking statements.

For more information, please contact: Lawrence Pemble or Judy Zakreski Chindex International, Inc. Tel: 1-301-215-7777

Chindex International, Inc.

CONTACT: Judy Zakreski or Lawrence Pemble, 1-301-215-7777, of Chindex

Web site: http://www.chindex.com/
http://www.unitedfamilyhospitals.com/

Researchers seek lab rats alternatives - The Age

Researchers seek lab rats alternatives The Age, Australia - Jan 28, 2008 The lab rat of the future may have no whiskers and no tail - and might not even be a rat at all. With a European ban looming on animal testing for cosmetics ...

CombiMatrix and Clarient Collaborate to Market, Sell Novel ... - FOXBusiness

CombiMatrix and Clarient Collaborate to Market, Sell Novel ... FOXBusiness - 59 minutes ago These technologies have a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, ...

deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women

REYKJAVIK, Iceland, Jan. 31 /PRNewswire-FirstCall/ -- Scientists from deCODE genetics today report the discovery of two common, single-letter variants in the sequence of the human genome (SNPs) that regulate one of the principle motors of evolution. Versions of the two SNPs, located on chromosome 4p16, have a genome-wide impact on the rate of recombination -- the reshuffling of the genome that occurs in the formation of eggs and sperm. Recombination is largely responsible for generating human diversity, the novel configurations of the genome that enable the species to adapt and evolve in an ever-changing environment. Yet remarkably, the versions of the SNPs that increase recombination in men decrease it in women, and vice versa. This highly unusual characteristic may enable the variants to help to maintain a fundamental tension crucial for evolutionary success: promoting the generation of significant diversity within a portion of the population but keeping the pace of this change within certain bounds, maintaining it relatively constant overall and so supporting the stability of the genome and the cohesiveness of the species.

"This is the latest in a series of landmark papers from deCODE in which we have utilized our unique capabilities in human genetics to elucidate some of the key mechanisms driving human evolution," said Kari Stefansson, CEO of deCODE. "We are also excited that we can now immediately enable individuals to see if they carry such variants, by folding the findings announced today -- and others we expect to publish in the near future -- into our deCODEme(TM) personal genome analysis service."

The deCODE team identified the SNPs through a genome-wide analysis of more than 300,000 SNPs in approximately 20,000 participants in the company's gene discovery programs. The SNPs, referred to as rs3796619 and rs1670533, are within the RNF212 gene, and are estimated to account for approximately 22% of paternal variability in recombination and 6.5% of maternal variability. Little is known about RNF212, though it is a mammalian homolog of a gene called ZHP-3 known to be crucial for the success of recombination in other organisms. The paper, entitled 'Sequence Variants in the RNF212 Gene Associate with Genomewide Recombination Rate,' is published today in the online edition of Science, at http://www.sciencemag.org/sciencexpress.

deCODE has made a number of breakthrough discoveries in the understanding of recombination, fertility and human evolution. In 2002, deCODE published the most detailed recombination map to date of the genome, demonstrating that there are hotspots and coldspots for recombination in all chromosomes, and that these are very different in women and men. This map provided a template for completing the final assembly of the sequence of the human genome. deCODE scientists then showed that recombination rate varies between families and between women; that recombination rate increases with the age of the mother; and that higher recombination rate correlates with fertility, indicating that evolution appears to place a premium on the generation of human diversity. In 2005, deCODE identified a genetic variant that correlates with higher recombination rate, the first genetic variant ever demonstrated to be under positive evolutionary selection in human populations in real time. References for these and all deCODE's major discoveries can be found at http://www.decode.com/.

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery -- our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at http://www.decode.com/; on our diagnostics website at http://www.decodediagnostics.com/; and, for our pioneering personal genome analysis service, at http://www.decodeme.com/.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

Contacts: Berglind Olafsdottir Edward Farmer Joy Bessenger 354 570 2393 1 212 343 2819 1 212 481 3891 bro@decode.is edward.farmer@decode.is ir@decode.is

deCODE genetics

CONTACT: Berglind Olafsdottir, 1-354-570-2393, bro@decode.is, or Edward
Farmer, 1-212-343-2819, edward.farmer@decode.is, or Joy Bessenger,
1-212-481-3891, ir@decode.is, all of deCODE genetics

Web site: http://www.decode.com/
http://www.decodediagnostics.com/
http://www.decodeme.com/
http://www.sciencemag.org/sciencexpress

SENIOR DRUG DISCOVERY APPLICATIONS SCIENTIST - Nature.com (subscription)

SENIOR DRUG DISCOVERY APPLICATIONS SCIENTIST Nature.com (subscription), UK - 30 minutes ago ... on both in-house efforts to improve and apply drug discovery methodologies and on collaborative projects with pharmaceutical/biotechnology partners. ...

'Neuron birth' process modulates learning, memory - TopNews

'Neuron birth' process modulates learning, memory TopNews, India - 1 hour ago Postdoctoral fellow Chun-Li Zhang combined mouse genetics and gene transfer techniques to genetically engineer mice, something that allowed him to ...

CombiMatrix and Clarient Collaborate to Market, Sell Novel ... - CNNMoney.com

CombiMatrix and Clarient Collaborate to Market, Sell Novel ... CNNMoney.com - 1 hour ago These technologies have a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, ...

Foamix Signs Term Sheet to Acquire License to Organo-Boron Antifungal Molecules - Will Target the 1 Billion Dollars Fungal Infection Market

NESS ZIONA, and TEL AVIV, Israel, January 31 /PRNewswire/ -- Foamix Ltd. a leading worldwide developer of topical foams for dermatology and gynecology and Ramot at Tel Aviv University Ltd., have reached an agreement on the commercial terms of a worldwide exclusive license for Organo-Boron Antifungal Molecules which are useful for topical and systemic treatment of fungal disease.

Under the terms of the agreement, Foamix will have the exclusive rights to develop and commercialize Ramot's proprietary Organo-Boron compounds, which were developed by Prof. Amihay Freeman and his research team at Tel Aviv University, and which possess potent fungicidal activity, as demonstrated in laboratory studies. The financial terms of the agreement were not disclosed.

The total global market for antifungal agents was worth more than 1 billion in 2007 and will reach nearly 4 billion by 2012, a CAGR of 4.5%. The global sales of dermatological antifungal drugs were about billion. Particularly, the Ramot Organo-Boron drugs are expected to be effective for onychomycosis, fungal infection of the fingernails and toenails, with a global market of approximately .7 billion in 2005.

"This agreement is further evidence of Foamix's commitment to seek out novel treatments for important dermatological and gynecological conditions, that involve fungal infection," commented Dov Tamarkin, Ph.D., Foamix's CEO. "We believe that Organo-Boron therapy represents a promising pathway for the treatment of fungal disease; and that the Ramot compounds will be a strong addition to our current in-house dermatological and gynecological pipeline."

"We are very proud to partner with an industry leader such as Foamix," said Ms. Irit Ben-Chlouch, Ramot's Director of Business Development, Life Sciences. "Foamix earned its position as a leading drug development company through a series of successful projects with big pharma partners and we are confident that partnering with Foamix offers the best opportunity for our Organo-Boron drugs to reach the market successfully," he noted.

About Foamix

Headquartered in Ness Ziona, Israel, Foamix Ltd. is a leading developer of topical foams for dermatology and gynecology. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is a privately held company, whose business model is based on partnering with leading pharma companies to develop products utilizing its proprietary foam technologies. Foamix is currently collaborating with 8 pharmaceutical companies on 10 projects in the development of proprietary dermatological and gynecologic foam drugs, and has its own in-house pipeline of dermatological and gynecological drugs in foam presentation.

Foamix holds 3 patents and has 62 patents pending. For additional information please visit http://www.foamix.co.il/ About Tel Aviv University

Founded in 1963, Tel Aviv University is one of Israel's foremost research and teaching universities. Located in Israel's cultural, financial and industrial heartland, Tel Aviv University is at the forefront of basic and applied research in a wide variety of scientific research disciplines, including engineering, exact sciences, life sciences, medicine, social sciences, management, law, humanities and the arts. More information is available online at http://www.tau.ac.il/.

About Ramot at Tel Aviv University Ltd.

Ramot is the technology transfer company of Tel Aviv University. Ramot fosters, initiates, leads and manages the transfer of new technologies from university laboratories to the marketplace by performing all activities relating to the protection and commercialization of inventions and discoveries made by faculty, students and other researchers. Ramot provides a dynamic interface connecting industry to leading-edge science and innovation, offering new business opportunities in a broad range of emerging markets.

For more information, visit http://www.ramot.org/ Press inquiries: Sigal Maymon, Foamix Ltd, 972-8-9316233 or info@foamix.co.il.

Foamix Ltd

CONTACT: Press inquiries: Sigal Maymon, Foamix Ltd, 972-8-9316233 or
info@foamix.co.il.

Cats' Family Tree Rooted in Fertile Crescent - innovations report

Cats' Family Tree Rooted in Fertile Crescent innovations report, Germany - 14 minutes ago Leslie Lyons, an authority on cat genetics and principal investigator on this study, said: "More than 200 genetic disorders have been identified in modern ...

I Love Dogs, So Why Did I Have to Kill a Happy, Healthy Animal? - Dog Magazine dot net

I Love Dogs, So Why Did I Have to Kill a Happy, Healthy Animal? Dog Magazine dot net, UK - 1 hour ago He couldna t help the fact that his genetics and appearance categorised him as dangerous. He was young, healthy and apparently very friendly. ...

Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study

AMSTERDAM, January 31 /PRNewswire/ -- Oncology focused biopharmaceutical product development company Kiadis Pharma announced today that it has successfully finalized its Rhitol(TM) Phase II clinical trial with the last patient completing its six month treatment cycle. Rhitol(TM) is evaluated as treatment for patients with extensive chronic Graft versus Host Disease (GvHD) intolerant or resistant to standard immunosuppressive treatment.

The current preliminary clinical results demonstrate an excellent safety profile for Rhitol(TM) and evidence of efficacy in the alleviation of the symptoms associated with chronic Graft versus Host Disease. After this clinical study was closed for enrollment mid 2007 Kiadis Pharma allowed new patients to be treated under a compassionate protocol. The successful completion of the Phase II clinical trial of Rhitol(TM) paves the way for a phase III study and Kiadis Pharma is planning to file for a phase III multi center clinical trial in the USA and Canada within the next few months.

Manja Bouman, CEO Kiadis Pharma comments: "We are very pleased with the positive outcome of this study and the potential shown by Rhitol(TM). This product would fulfill a significant unmet medical need since patients with chronic GvHD resistant or intolerant to immunosuppressive drugs have no other standard treatment option available to them and this disease can subsequently develop into a life-threatening condition."

To read the complete press releases please go to http://www.kiadis.com

Disclaimer:

English release is provided by Kiadis Pharma. Equivalent translations are from a third party.

Kiadis Pharma

For more information please contact: Kiadis Pharma B.V., Eefje Simpelaar, Director Communications, Email: e.simpelaar@kiadis.com, Tel: 31-20-8884815, Mob 31-610829344

HIV patients in India do not get dementia, say Bangalore scientist - Economic Times

HIV patients in India do not get dementia, say Bangalore scientist Economic Times, India - 1 hour ago Subtype C is not prone to dementia because the protein TAT that effects the brain cell undergoes a genetic change in India and results in lack of dementia. ...

San Marcos middle-schoolers dig into science - North County Times

San Marcos middle-schoolers dig into science North County Times, CA - 1 hour ago A university honor student in molecular cell biology and biotechnology, Gonzalez will graduate from Cal State San Marcos in May. ...

Konecsni to head up Plant Biotech Institute - StarPhoenix

Konecsni to head up Plant Biotech Institute StarPhoenix, Canada - 2 hours ago "They correctly recognize that there is a huge opportunity with plant biotechnology with environmental climate change issues and biofuels development. ...

Genmab's Financial Calendar for 2008

COPENHAGEN, Denmark, January 31 /PRNewswire/ -- Genmab A/S (OMX: GEN) announces its financial calendar for 2008 as follows:

EVENT DATE Publication of the Annual Report for 2007 Monday, March 31, 2008 Annual General Meeting 2008 Wednesday, April 23, 2008 Publication of the Interim Report for the Wednesday, May 28, 2008 first quarter 2008 Publication of the Interim Report for the Wednesday, August 27, 2008 first half 2008 Publication of the Interim Report for the Wednesday, October 29, 2008 first nine months 2008

Publication of the financial reports will be after market close on the date of the event.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.

Contact: Helle Husted, Sr. Director, Investor Relations, T: 45-33-44-77-30, M: 45-25-27-47-13, E: hth@genmab.com.

Genmab A/S

Contact: Helle Husted, Sr. Director, Investor Relations, T: 45-33-44-77-30, M: 45-25-27-47-13, E: hth@genmab.com.

Oncolytics Biotech Inc. Proceeds to Full Enrolment in US Phase II ... - CNNMoney.com

Oncolytics Biotech Inc. Proceeds to Full Enrolment in US Phase II ... CNNMoney.com - 31 minutes ago Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. ...

Incubator graduates find lab space costly - Frederick News Post (subscription)

Incubator graduates find lab space costly Frederick News Post (subscription), MD - 39 minutes ago A study by the Maryland Technology Development Corp., or TEDCO, released Monday finds that many incubator graduates, particularly biotechnology companies, ...

Body Sculpting Secrets - Huffington Post

Body Sculpting Secrets Huffington Post, NY - 23 minutes ago While the concept is age old, the stakes today are higher as cosmetic technology flirts with genomics, promising yet newer ways to sculpt our bodies -- at ...

Estimating Excess Mortality in Post-Invasion Iraq - New England Journal of Medicine (subscription)

Estimating Excess Mortality in Post-Invasion Iraq New England Journal of Medicine (subscription), MA - 1 hour ago Ms. Brownstein is a doctoral student in the Department of Genetics at Yale University, New Haven, CT. Dr. Brownstein is a faculty member in the Children's ...

Pharmaceutical manufacturing: people on the move - In-PharmaTechnologist.com

Pharmaceutical manufacturing: people on the move In-PharmaTechnologist.com, UK - 36 minutes ago ... consultant focused on the development of business operations, technical and supply chain solutions for biotechnology and pharmaceutical companies. ...